Hopewell, New Jersey, United States, December 2024 – ProBio, a global leader in contract development and manufacturing (CDMO) services, has announced significant leadership changes effective December 1, 2024, appointing Allen Guo as Chief Executive Officer (CEO), Whitney Winters as Senior Vice President of U.S. Business Development, and Michael Vreeland as U.S. Site Head and Interim Head of Process Development. These strategic appointments underline ProBio’s commitment to advancing life-changing therapies for biotech and pharmaceutical industries globally.
Allen Guo, who joined ProBio in 2021, brings 16 years of leadership experience across Janssen, Lonza, Becton Dickinson, and Patheon. His business development efforts have significantly contributed to ProBio’s revenue growth, supporting projects from discovery through pre-commercial Biologics License Application (BLA) stages.
Guo expressed his vision for the role: “It is an honor to take on this role and continue to contribute to ProBio’s mission. Together with our talented team, I am committed to driving innovation, delivering quality solutions, and empowering our customers to develop therapies that make a lasting impact on patients’ lives.”
Whitney Winters, with 17 years of sales and marketing expertise, has been instrumental since joining ProBio as Vice President of Commercial Excellence earlier this year. She now leads business development and marketing strategies to drive U.S. market expansion.
Winters shared her enthusiasm:“I am thrilled to take on this role at such an exciting time for ProBio. With our cutting-edge CDMO capabilities, I look forward to expanding our U.S. presence and collaborating with our customers to bring transformative therapies to patients around the world.”
Michael Vreeland oversees operations at ProBio’s state-of-the-art facility in Hopewell, New Jersey, serving as a hub for plasmid DNA and viral vector production. With 16 years of cGMP manufacturing experience, his leadership will enhance ProBio’s operational excellence.
Vreeland remarked: “I am excited to lead ProBio’s U.S. manufacturing operations and help deliver high-quality solutions that support our customers in advancing life-changing therapies. Together, we will drive operational excellence and continue to fulfill ProBio’s mission of improving patient outcomes.”
These leadership changes reflect ProBio’s strategy to foster innovation and collaboration while expanding its impact in the U.S. and globally. The company’s Chairman, Li Zhu, commended the appointments:
“Allen, Whitney, and Michael are uniquely qualified to lead ProBio into its next phase of growth. Their expertise and commitment to innovation and collaboration will ensure ProBio continues to empower our customers in delivering therapies that transform patients’ lives.”
About ProBio
ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation biologics and advanced therapies. As a fully integrated, end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports partners in optimizing drug development, accelerating time-to-market, and providing comprehensive life-cycle support. Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new therapeutics, enabling its partners to navigate the complexities of human disease with innovative and adaptable therapeutic approaches.
Click Here to Join HR TODAY WhatsApp Channel
Read Also : People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
